Generation Bio Co. (GBIO) |
| 5.34 0 (0%) 02-10 09:30 |
| Open: | 5.34 |
| High: | 5.34 |
| Low: | 5.34 |
| Volume: | 551,924 |
| Market Cap: | 36(M) |
| PE Ratio: | -0.57 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 5.77 |
| Resistance 1: | 5.59 |
| Pivot price: | 5.58 |
| Support 1: | 5.31 |
| Support 2: | 4.42 |
| 52w High: | 7.516 |
| 52w Low: | 3.004 |
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| EPS | -76380000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -39.254 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -2.00 |
| Return on Assets (ttm) | 20.0 |
| Return on Equity (ttm) | -27.4 |
Sun, 17 May 2026
Generation Bio stock (US37148B1061): Trial momentum keeps investors watching - AD HOC NEWS
Thu, 14 May 2026
Atlas Venture amends 13G/A on GBIO holdings (GBIO) - Stock Titan
Tue, 10 Feb 2026
Generation Bio pays landlord $21.5M to escape lease early after Xoma buyout - The Business Journals
Tue, 10 Feb 2026
XOMA Completes Acquisition and Delisting of Generation Bio - The Globe and Mail
Mon, 09 Feb 2026
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share - Investing.com
Mon, 09 Feb 2026
XOMA Royalty acquires Generation Bio (NASDAQ: GBIO) in cash and CVR buyout - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |